ATE485820T1 - Verwendung von n-(dibenz (b,f)oxepin-10-ylmethyl)-n-methyl-n-prop-2-inyl min (omigapil) zur prophylaxe und/oder behandlung von muskeldystrophie - Google Patents

Verwendung von n-(dibenz (b,f)oxepin-10-ylmethyl)-n-methyl-n-prop-2-inyl min (omigapil) zur prophylaxe und/oder behandlung von muskeldystrophie

Info

Publication number
ATE485820T1
ATE485820T1 AT06777007T AT06777007T ATE485820T1 AT E485820 T1 ATE485820 T1 AT E485820T1 AT 06777007 T AT06777007 T AT 06777007T AT 06777007 T AT06777007 T AT 06777007T AT E485820 T1 ATE485820 T1 AT E485820T1
Authority
AT
Austria
Prior art keywords
prophylaxis
treatment
omigapil
oxepine
dibenz
Prior art date
Application number
AT06777007T
Other languages
English (en)
Inventor
Thomas Meier
Markus Rueegg
Original Assignee
Santhera Pharmaceuticals Ch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santhera Pharmaceuticals Ch filed Critical Santhera Pharmaceuticals Ch
Application granted granted Critical
Publication of ATE485820T1 publication Critical patent/ATE485820T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT06777007T 2005-08-25 2006-08-22 Verwendung von n-(dibenz (b,f)oxepin-10-ylmethyl)-n-methyl-n-prop-2-inyl min (omigapil) zur prophylaxe und/oder behandlung von muskeldystrophie ATE485820T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05018530A EP1757284A1 (de) 2005-08-25 2005-08-25 Verwendung von N-(dibenz(b,f)oxepin-10ylmethyl)-N-methyl-N-prop-2-ynylamine (Omigapil) zur Vorbeugung oder Behandlung der Muskulardystrophy
PCT/EP2006/008237 WO2007022951A1 (en) 2005-08-25 2006-08-22 Use of n-(dibenz (b,f)oxepin-10-ylmethyl)-n-methyl-n-prop-2-ynylamine (omigapil) for the prophylaxis and/or treatment of muscular dystrophy

Publications (1)

Publication Number Publication Date
ATE485820T1 true ATE485820T1 (de) 2010-11-15

Family

ID=35207868

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06777007T ATE485820T1 (de) 2005-08-25 2006-08-22 Verwendung von n-(dibenz (b,f)oxepin-10-ylmethyl)-n-methyl-n-prop-2-inyl min (omigapil) zur prophylaxe und/oder behandlung von muskeldystrophie

Country Status (17)

Country Link
US (1) US7999002B2 (de)
EP (2) EP1757284A1 (de)
JP (1) JP4852100B2 (de)
AT (1) ATE485820T1 (de)
AU (1) AU2006284140B2 (de)
CA (1) CA2620891C (de)
CY (1) CY1111067T1 (de)
DE (1) DE602006017855D1 (de)
DK (1) DK1924255T3 (de)
ES (1) ES2351577T3 (de)
MX (1) MX2008002563A (de)
NZ (1) NZ565194A (de)
PL (1) PL1924255T3 (de)
PT (1) PT1924255E (de)
SI (1) SI1924255T1 (de)
WO (1) WO2007022951A1 (de)
ZA (1) ZA200800999B (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1842539A1 (de) * 2006-04-05 2007-10-10 Santhera Pharmaceuticals (Schweiz) AG Verwendung von N-(dibenz(b,f)oxepin-10-ylmethyl)N-methyl-N-prop-2-ynylamine (Omigapil) zur Vorbeugung und/oder Behandlung von angeborener Muskeldystrophie oder Myopathie verursacht durch einen Kollagen IV Mangel
JP6819337B2 (ja) * 2017-02-10 2021-01-27 セイコーエプソン株式会社 印刷装置、及び、印刷装置の制御方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780244A (en) * 1993-09-27 1998-07-14 La Jolla Cancer Research Foundation Changes in laminin subunit composition are diagnostic of Fukuyama congenital muscular dystrophy
US5863743A (en) * 1994-08-12 1999-01-26 University Of Iowa Research Foundation Merosin deficiency-type congenital muscular dystrophy
DE59607332D1 (de) * 1995-02-08 2001-08-30 Novartis Ag Antineurodegenerativ wirksame 10-Aminoaliphatyl-dibenz- b,f oxepine
AR008371A1 (es) 1996-05-30 2000-01-19 Novartis Ag Una sal de adicion con acido de una 10-aminoalifatil-dibenz[b,f],oxepina, su empleo; procedimiento para su elaboracion, una 10-aminoalifatil-dibenz[b,f]oxepina, una preparacion farmaceutica que contiene dicha sal o dicha oxepina y un procedimiento para el tratamiento de enfermedades neurodegenerativ
US6495376B1 (en) * 1999-02-18 2002-12-17 Beth Israel Deaconess Medical Center Methods and compositions for regulating protein-protein interactions
DZ3083A1 (fr) * 1999-02-19 2004-06-02 Smithkline Beecham Corp Composés nouveaux inhibiteurs de protéases, procédé pour leur préparation et compositions pharmaceutiques les conentant.
US7563862B2 (en) * 2001-08-24 2009-07-21 Neuren Pharmaceuticals Limited Neural regeneration peptides and methods for their use in treatment of brain damage
US7078379B2 (en) * 2002-06-03 2006-07-18 Santhera Pharmaceuticals (Schweiz) Gmbh Treatment of congenital muscular dystrophies
US7977049B2 (en) * 2002-08-09 2011-07-12 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
TW200505435A (en) * 2003-01-29 2005-02-16 Novartis Ag Treatment of ocular disorders
EP1454627A1 (de) 2003-03-06 2004-09-08 MyoContract Ltd. Alpha-Keto-Carbonyl-Verbindungen als Calpainhemmer
US8043614B2 (en) * 2004-03-09 2011-10-25 Ahlfors Jan-Eric W Autogenic living scaffolds and living tissue matrices: methods and uses thereof
AR046320A1 (es) 2003-11-06 2005-11-30 Novartis Ag Composiciones farmaceuticas estabilizadas de dibenzo-oxepina.
EP1842539A1 (de) * 2006-04-05 2007-10-10 Santhera Pharmaceuticals (Schweiz) AG Verwendung von N-(dibenz(b,f)oxepin-10-ylmethyl)N-methyl-N-prop-2-ynylamine (Omigapil) zur Vorbeugung und/oder Behandlung von angeborener Muskeldystrophie oder Myopathie verursacht durch einen Kollagen IV Mangel

Also Published As

Publication number Publication date
EP1757284A1 (de) 2007-02-28
JP2009505998A (ja) 2009-02-12
JP4852100B2 (ja) 2012-01-11
MX2008002563A (es) 2008-03-25
ES2351577T3 (es) 2011-02-08
PT1924255E (pt) 2010-11-08
SI1924255T1 (sl) 2011-02-28
AU2006284140A1 (en) 2007-03-01
ZA200800999B (en) 2008-11-26
PL1924255T3 (pl) 2011-09-30
CY1111067T1 (el) 2015-06-11
EP1924255A1 (de) 2008-05-28
DE602006017855D1 (de) 2010-12-09
EP1924255B1 (de) 2010-10-27
CA2620891A1 (en) 2007-03-01
NZ565194A (en) 2010-04-30
DK1924255T3 (da) 2011-01-31
WO2007022951A1 (en) 2007-03-01
US20100160269A1 (en) 2010-06-24
AU2006284140B2 (en) 2009-08-20
CA2620891C (en) 2010-11-09
US7999002B2 (en) 2011-08-16

Similar Documents

Publication Publication Date Title
EA201000050A1 (ru) Замещенные бициклолактамные соединения
ATE376828T1 (de) Verwendung von rotigotin zur behandlung und prävention des parkinson-plus-syndroms
NO20081315L (no) Benzokinazolinderivater og deres anvendelse ved behandling av benlidelser
CY1107956T1 (el) Χρηση υποκατεστημενων 2-αμινοτετραλινιων για την προληπτικη αντιμετωπιση της νοσου του παρκινσον
ATE534391T1 (de) 3,11b-cis-dihydrotetrabenazin zur behandlung von psychosen
ATE450514T1 (de) Piperazinylalkylpyrazol-derivate zur verwendung als selektive calciumkanalblocker des t-typs und verfahren zu ihrer herstellung
NO20082096L (no) Azaindol-2-karboksamidderivativer
ATE547417T1 (de) Dihydropyrimidinverbindungen und ihre verwendungen bei der herstellung von medikamenten zur behandlung und prävention antiviraler krankheiten
EA200870577A1 (ru) Конденсированные трициклические сульфонамидные ингибиторы гамма-секретазы
MX2010003948A (es) N-fenil-birrolidin ureas sustituidas y uso terapeutico de las mismas.
TNSN04203A1 (en) Benzoxazinone-derived compounds, their preparation and use as medicaments
MXPA06009475A (es) Derivados de quinazolina y usos terapeuticos de los mismos.
ATE548032T1 (de) Verwendung von chlorguanabenzderivaten zur behandlung von mit polyglutaminexpansion assoziierten erkrankungen
EA200601194A1 (ru) Новые производные бензофурана, используемые для профилактики или лечения нарушений, связанных с 5-ht-рецептором
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
BRPI0508051A (pt) derivados de heteroarilaminopirazol utilizáveis para o tratamento de diabetes
EA200601837A1 (ru) Бензоксазины для лечения заболеваний дыхательных путей
MA32841B1 (fr) Composés de cycloundeca depsipeptides et leur utilisation comme médicament
MX2009004770A (es) Compuestos de carbamato para usarse en el tratamiento de la depresion.
DE602006010738D1 (de) Pyrroloä2,3-cüpyridinderivate
EA200900269A1 (ru) Лекарственные комбинации для лечения заболеваний дыхательных путей
DE602004019778D1 (de) Verwendung von 2-amino-1,3-propandiolderivaten zur herstellung eines medikaments zur behandlung von bestimmten schmerzen
MX2009005242A (es) Derivados de 3-(hetero)arilisoquinolinamida sustituida en posición 5, 6 o 7 y uso terapeutico del mismo.
ATE485820T1 (de) Verwendung von n-(dibenz (b,f)oxepin-10-ylmethyl)-n-methyl-n-prop-2-inyl min (omigapil) zur prophylaxe und/oder behandlung von muskeldystrophie
ATE429910T1 (de) Chlor enthaltende guanabenz derivate zur behandlung von prionerkrankungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1924255

Country of ref document: EP